PubMed Health⌕ Search

Biomedical subjects

D Burnea

Publications and source records attributed to D Burnea.

48 records · Page 3Linked to original sources
PubMedDate not supplied

[Current possibilities of echography in pneumological diagnosis (preliminary note)].

Various types of echographies are presented, and it is concluded that the bi-dimensional echography, also called type B or echo-tomography is the most useful for the study of pulmonary affections, and of compact formations in contact with the pulmonary tissues. With the aid of Model E.D.B. Unirad sonograph (Technicare, USA), and of the Scintron 5 computer (Scintag, Berthold, Switzerland) 6 patients with pleurisy of various extension, one patient with fibrothorax, and 2 patients with pulmonary tumours have been examined. Five of the cases are presented. Echotomography has demonstrated its usefulness in measuring the thickness of the thoracic wall, in establishing by means of a non-invasive technique the solid or fluid character of pleural affections, in assessing the structure of pachypleuritis and in detecting changes induced by tumours, or atelectasia in the vicinity of the pleura. However, the method does not provide information on round peripheral tumours which do not come into contact with the pleura. Also this method cannot replace other methods already used in the pneumological practice, but can provide supplementary informations without any risks for the patient.

Female↗
PubMedDate not supplied

[Preliminary results of the use of a new derivative of rifamycin SV in the treatment of sarcoidosis].

Seven patients with advanced forms of mediastino-pulmonary sarcoidosis (involvement of the pulmonary parenchyma, and restrictive respiratory syndrome), confirmed by histopathologic investigation, have been treated with a new SV-rifamycin derivative, 1246-EH, or "Reprimum" without any other association. Reprimun was given in daily doses of 10 mg/kg of body weight for a period of two weeks, then, for another 4-5 weeks, the drugs was given intermittently in doses of 15 mg/kg of body weight twice weekly. Between two cycles of therapy a period of 14 days was free of drug administration. In all patients the treatment with the new derivative was well tolerated. The treatment was not followed by adrenal deficiencies, neither was noted obesity, bone decalcification, gastric ulcers, etc., which are commonly associated with prolonged corticoid therapy. The treatment with "Reprimun" efficient for all patients. A clear clinical and X-ray improvement was noted after the first three months of treatment with the new drug. Respiratory function, as well as clinical and radiological signs improved, the serum immunologic parameters, and the biochemical ones were also significantly improved (Ig, C3 total serum proteins and gammaglobulins). All parameters which were tested were finally improved and became normal. In only two of the seven patients the radiological aspects of the lung suggested the presence of sequellae at the end of the treatment. In these two patients there was a persistant reduction in the respiratory volume, as well as a discret hypoxemia. However, both these patients had a more advanced form of the disease, with extensive pulmonary fibrosis, and in these cases prolonged corticoid therapy which had previously been applied had failed. Reprimun had an immunological-modulatory effect in all patients, resulting in normal levels of IgG, IgA, and C3 in the first three months of therapy. There was a direct correlation between the normalization of immunological indicators and the good evolution of the diseases, a fact which suggests once again the existence of some immune mechanisms involved in the maintenance of sarcoidosis.

Adult↗
PubMedDate not supplied

[Risk of bronchopulmonary cancer in patients with chronic obstructive bronchopneumopathy].

A total of 477 cases have been followed, presenting with chronic obstructive bronchopneumopathy, and another 151 cases with chronic bronchitis without obstructive syndrome, over a median duration of 5 years. In the first lot of patients 37 cases of bronchopulmonary cancer have been recorded over this period of time, of which 35 in 333 male patients (10.5%), and 2 in 144 women (1.4%). The annual rate of bronchopulmonary cancer was of 1.9% in males, and of 0.2% in females. In the group of patients with simple bronchitis only 3 cases of bronchopulmonary cancer have been recorded, with an annual rate of 0.4%. In male patients with chronic obstructive bronchopneumopathy the annual risk of bronchopulmonary cancer is of 1900 0/0000, 60 times greater than in the general population, where it is of 30 0/0000. A comparative analysis of the three groups: chronic simple bronchitis, chronic obstructive bronchopneumopathy and chronic obstructive bronchopneumopathy complicated with bronchopulmonary cancer shows that in the last group there are several outstanding features: a more advanced median age, intensive (heavy) smoking, a more advanced degree of chronic alcohol intoxication, frequent professional exposure, genetic deficiencies of I.A.T., prolonged corticoid therapy in the antecedents, and a higher proportion of associated diseases. In general this group is more exposed to risk factors, and has a higher risk of alteration of the defense mechanisms of the organism. However, a more detailed analysis is necessary for detecting the factors involved in the genesis of bronchopulmonary cancer in patients with chronic obstructive bronchopneumopathies.

Adult↗